RNAi therapeutics have come a long way since they were first introduced. While the industry experienced some setbacks early on, scientists remain confident that RNAi has the potential to create a class of “superdrugs” that could revolutionize modern medicine. Investors should therefore at least consider keeping some exposure in their portfolios.
The three companies above all represent potential plays in this market with upcoming clinical trials and pre-clinical results. But, RXi Pharmaceuticals Inc. represents perhaps the most under appreciated play, with its unique platform that redefines how RNAi is delivered into cells. As a result, investors may want to keep a close eye on the stock moving forward.
News 
Market Data 
Discover 
